Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta®1 Tablets, 1 mg and 5 mg. Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.81 USD | +0.40% | +9.49% | -3.40% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 157B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Glenmark Pharmaceuticals Reaches Settlement Agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg